重组人生长激素治疗ISS及GHD患儿的疗效及安全性分析

目的探讨重组人生长激素治疗特发性矮小症(ISS)及生长激素缺乏症(GHD)的临床疗效及安全性。方法选择2011年9月至2012年12月在我院采用重组人生长激素治疗的28例ISS及30例GHD患儿为研究对象,记录治疗前后患儿生长速率(GV)、体重、身高、骨龄、身高标准差计数(HtSDS)、胰岛素样生长因子-1(IGF-1)水平及不良反应发生率。结果治疗后患儿GV、HtSDS与治疗前比较差异有统计学意义(P<0.05);治疗后IGF-1水平显著升高(P<0.05);两组治疗前后体重、身高、骨龄均未见显著改变(P>0.05);ISS患儿GV与IGF-1水平未见相关性(r=0.235,P>0.05);GHD患儿GV与IGF-1水平显著相关(r=0.638,P<0.05);ISS及GHD患儿不良反应发生率12.1%,经处置后患儿均顺利完成治疗。结论重组人生长激素可促进ISS及GHD患儿生长,不会使骨龄明显提前,安全性好。

Effect and safety analysis of recombinant human growth hormone in treatment of ISS and GHD in children

Objective To explore the clinical efficacy and safety of recombinant human growth hormone in treatment of ISS and GHD in children. Methods From September 2011 to December 2012,28 children with ISS and 30 children with GHD treated with recombinant human growth hormone were selected as research subjects. GV,body weight,body height,bone age,HtSDS,IGF-1 and adverse reaction rate were recorded. Results GV and HtSDS of ISS children had significant difference compared with pre-treatment; IGF-1 level greatly increased after treatment in ISS children（ P〈0. 05）;GV and HtSDS of GHD patients were superior to pre-treatment（ P〈0. 05）; Compared with pre-treatment,IGF-1 level greatly increased after treatment（ P〈0. 05）; There were no significant difference of body weight,body height and bone age before and after therapy in ISS and GHD patients（ P〉 0. 05）; GV had no significantly positive correlation with IGF-1 in ISS patients（ r = 0. 235,P〉 0. 05）,while it had correlation in GHD patients（ r = 0. 638,P〈0. 05）. The adverse reaction rate was 12. 1% in ISS and GHD patients,and all the subjects completed the treatment. Conclusion Recombinant human growth hormone for ISS and GHD in children can promote the growth,and accelerate the increment of bone age with good safety.